Michael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $955,319.67. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.62, for a total transaction of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total value of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00.
• On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $407.32, for a total value of $6,109,800.00.
• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The stock was sold at an average price of $374.46, for a total transaction of $5,504,562.00.

United Therapeutics Trading Up 0.5 %

Shares of United Therapeutics stock opened at $372.75 on Thursday. The company’s 50-day moving average price is $365.77 and its 200-day moving average price is $356.81. The company has a market cap of $16.64 billion, a price-to-earnings ratio of 16.37, a PEG ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the prior year, the firm posted $5.38 earnings per share. The business’s quarterly revenue was up 22.9% on a year-over-year basis. On average, sell-side analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. LADENBURG THALM/SH SH raised their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, UBS Group upped their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $378.36.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the fourth quarter valued at approximately $25,000. USA Financial Formulas purchased a new position in shares of United Therapeutics during the 3rd quarter valued at about $33,000. Brooklyn Investment Group bought a new stake in United Therapeutics in the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP purchased a new stake in United Therapeutics in the third quarter worth approximately $82,000. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.